3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
3
Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Melanoma
1
Hemangiosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Fulvestrant
58
Trastuzumab
49
Capecitabine
48
Letrozole
45
pembrolizumab
41
Carboplatin
41
Paclitaxel
39
Cyclophosphamide
38
ribociclib
37
pertuzumab
36
abemaciclib
36
Blood Specimen Collection
31
Specimen Handling
28
trastuzumab deruxtecan
27
Docetaxel
27
Surveys and Questionnaires
26
Anastrozole
25
exemestane
24
Tamoxifen
24
palbociclib
21
130-nm albumin-bound paclitaxel
21
Magnetic Resonance Spectroscopy
20
Biopsy
19
sacituzumab govitecan
18
eribulin
18
Radiotherapy
18
Gemcitabine
18
olaparib
17
Injections
17
Epirubicin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Breast Neoplasms
×
sarilumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled